NASDAQ: TNGX Tango Therapeutics, Inc. 8-K

Tango Therapeutics raises $566.5M in public offering, extending cash runway into 2030

Filed June 10, 2026 · Period ending June 9, 2026 · ~1 min read

Key Changes

high

Tango sold 18.2 million shares at $30.00 each plus 1.8 million pre-funded warrants at $29.999, raising approximately $566.5 million after fees through J.P. Morgan and Leerink Partners.

Item 1.01 verify on EDGAR →
high

Proceeds will fund R&D, pivotal trial expenses, commercialization preparation, and operations. Combined with existing cash, this extends the company's runway into 2030.

Item 1.01 verify on EDGAR →
medium

Pre-funded warrants have a nominal $0.001 exercise price and are immediately exercisable with no expiration, but include ownership caps at 4.99% or 9.99% to prevent concentrated dilution.

Item 1.01 verify on EDGAR →
medium

The offering is expected to close on June 11, 2026, subject to customary closing conditions. Underwriters have a 30-day option to purchase up to 3 million additional shares.

Item 1.01 verify on EDGAR →

Summary

Tango Therapeutics completed a substantial capital raise of approximately $566.5 million through an underwritten public offering. The company sold 18.2 million common shares at $30.00 per share and 1.8 million pre-funded warrants at $29.999 each, with J.P. Morgan and Leerink Partners serving as lead underwriters.

The pre-funded warrants are essentially equivalent to common stock, carrying only a $0.001 exercise price and being immediately exercisable without expiration. For retail investors, this offering significantly strengthens Tango's financial position, extending the company's cash runway into 2030.

Management plans to deploy the capital toward research and development, pivotal clinical trials, and preparation for potential commercialization of product candidates. The substantial dilution—approximately 20 million new shares—will impact existing shareholders' ownership percentage, though the extended runway reduces near-term financing risk. Investors should monitor the company's progress on the pivotal trials mentioned in the filing, as successful trial outcomes would justify the capital deployment and potentially drive value creation that offsets the dilution. The 2030 runway also signals management's confidence in reaching key value-inflection milestones without needing additional capital raises in the near term.

Section-by-Section Diff

Event · Item 1.01 — Entry into a Material Definitive Agreement

~1,400 words

Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.

4 Added

Added Equity offering high

Added in current filing · verify on EDGAR →

On June 9, 2026, Tango Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives (the “Representatives”) to the several underwriters named in the Underwriting Agreement (collectively, the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 18,166,667 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,833,395 shares of Common Stock (such shares issuable upon exercise of the Pre-Funded Warrants, the “Pre-Funded Warrant Shares”). Each Share was offered and sold at an offering price of $30.00 before deducting underwriting discounts and commissions and each Pre-Funded Warrant was offered and sold at an offering price of $29.999 which is equal to the offering price per Share less the $0.001 exercise price of each Pre-Funded Warrant, before deducting underwriting discounts and commissions.

Tango sold 18.2 million shares at $30.00 each and 1.8 million pre-funded warrants at $29.999 each through J.P. Morgan and Leerink Partners. The pre-funded warrants have a nominal $0.001 exercise price and are immediately exercisable with no expiration. Underwriters also received a 30-day option to purchase up to 3 million additional shares at the same price.

Added Net proceeds and use of funds high

Added in current filing · verify on EDGAR →

The Company estimates that the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company are approximately $566.5 million. The Company intends to use the net proceeds from the Offering for general corporate purposes, including research and development expenses, expenses relating to the Company’s pivotal trial and preparation for the potential commercialization of one or more of the Company’s product candidates, general and administrative expenses and capital expenditures. Based upon the Company’s current operating plan, it believes that the net proceeds from this Offering, together with its existing cash, cash equivalents and investments, will enable it to fund its operating expenses and capital expenditure requirements into 2030.

Tango expects to net approximately $566.5 million after fees. The company plans to use proceeds for R&D, pivotal trial expenses, commercialization preparation, G&A, and capex. Management believes this capital, combined with existing cash, extends the cash runway into 2030.

Added Offering timing and closing medium

Added in current filing · verify on EDGAR →

The Offering is expected to close on June 11, 2026, and is subject to the satisfaction of customary closing conditions.

The offering is scheduled to close on June 11, 2026, subject to standard closing conditions. This is a near-term event occurring two days after the underwriting agreement was signed.

Added Pre-funded warrant ownership limitations medium

Added in current filing · verify on EDGAR →

Under the Pre-Funded Warrants, the Company may not effect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant (i) if immediately prior to the exercise, a holder (together with its affiliates), beneficially owns an aggregate number of shares of Common Stock greater than 4.99% or 9.99%, as applicable (the “Maximum Percentage”) of the total number of issued and outstanding shares of Common Stock of the Company without taking into account any Pre-Funded Warrant Shares, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such Pre-Funded Warrant Shares, which such percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon 61 days’ notice to the Company.

The pre-funded warrants include ownership caps preventing holders from exercising if they would exceed 4.99% or 9.99% beneficial ownership. Holders can adjust this cap up to 19.99% with 61 days' notice. This structure prevents immediate dilution from large warrant exercises.

Event · Item 9.01 — Financial Statements and Exhibits

~100 words

Tango Therapeutics completed an underwritten public offering with pre-funded warrants on June 9, 2026.

2 Added

Added Underwritten public offering high

Added in current filing · verify on EDGAR →

Underwriting Agreement, dated June 9, 2026, among Tango Therapeutics, Inc, J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters named in Schedule A thereto.

Tango Therapeutics entered into an underwriting agreement on June 9, 2026 with J.P. Morgan Securities and Leerink Partners as lead underwriters for a public offering. The filing includes pre-funded warrants as part of the offering structure, suggesting the company is raising capital through equity or equity-linked securities.

Added Pre-funded warrants medium

Added in current filing · verify on EDGAR →

Form of Pre-Funded Warrant

The company issued pre-funded warrants as part of the offering. Pre-funded warrants are typically used to allow investors to effectively purchase shares at a nominal exercise price, providing an alternative to direct common stock purchases while potentially offering tax or regulatory advantages to certain investors.